Xvivo Perfusion AB (LTS:0RKL)
kr 471.13141 -2.4818 (-0.52%) Market Cap: 15.12 Bil Enterprise Value: 14.69 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Q4 2021 Xvivo Perfusion AB Earnings Call Transcript

Jan 27, 2022 / 01:00PM GMT
Release Date Price: kr255.97 (+11.78%)
Operator

Ladies and gentlemen, welcome to the XVIVO Group Report on Operations Q4 2021.

I will now hand over to Dag Andersson, CEO. Sir, please go ahead.

Dag Andersson;publ;President;CEO
Xvivo Perfusion AB

()-&

Thank you very much. So welcome to XVIVO Q4 call. And the presenters today, it's me Dag Andersson; and my CFO, Kristoffer Nordström. And I would like to start by summarizing some of the highlights. During the quarter, we had a very, let's say, interesting quarter, many things happened, positive things. We achieved, I must say, great organic growth in the quarter, 32%; and for the full year, 27%.

Earnings growth total amounted to 42% in the quarter, and adjusted EBITDA margin of 11%. The EBITDA number includes certain nonrecurring items amounting to approximately SEK 4 million, which Kristoffer will touch upon later. During fourth quarter and so -- and in connection with the acquisition of the U.S. company STAR Teams early November, we established a third business area, Services. So we now

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot